S'abonner

Airway and parenchymal transcriptomics in a novel model of asthma and COPD overlap - 04/10/22

Doi : 10.1016/j.jaci.2022.04.032 
Xiaofan Tu, BMedSci(Hons) a, , Richard Y. Kim, PhD a, b, , Alexandra C. Brown, PhD a, Emma de Jong, PhD c, Bernadette Jones-Freeman, PhD a, d, Md Khadem Ali, PhD a, Henry M. Gomez, PhD a, Kurtis F. Budden, PhD a, Malcolm R. Starkey, PhD a, d, Guy J.M. Cameron, PhD a, Svenja Loering, MSc a, Duc H. Nguyen, PhD a, Prema Mono Nair, PhD a, Tatt Jhong Haw, PhD a, Charlotte A. Alemao, MSc a, Alen Faiz, PhD b, Hock L. Tay, PhD a, Peter A.B. Wark, MD, PhD a, Darryl A. Knight, PhD a, e, Paul S. Foster, DSc a, Anthony Bosco, PhD c, Jay C. Horvat, PhD a, Philip M. Hansbro, PhD a, f, , , Chantal Donovan, PhD a, b, ,
a Priority Centre for Healthy Lungs, Hunter Medical Research Institute and The University of Newcastle, Newcastle, Australia 
b Faculty of Science, School of Life Sciences, University of Technology Sydney, Sydney, Australia 
c Telethon Kids Institute, Centre for Health Research, The University of Western Australia, Nedlands, Australia 
d Department of Immunology and Pathology, Central Clinical School, Monash University, Melbourne, Australia 
e Providence Health Care Research Institute, Vancouver, British Columbia, Canada 
f Centre for Inflammation, Faculty of Science, School of Life Sciences, Centenary Institute and University of Technology Sydney, Sydney, Australia 

Corresponding author: Philip Hansbro, PhD, Centenary Institute, Building 93 RPA Hospital, Missenden Road, Camperdown, New South Wales 2050, Australia.Centenary InstituteBuilding 93 RPA HospitalMissenden RoadCamperdownNew South Wales2050Australia∗∗Chantal Donovan, PhD, University of Technology Sydney, PO Box 123, Broadway, Ultimo, New South Wales 2007, Australia.University of Technology SydneyPO Box 123BroadwayUltimoNew South Wales2007Australia

Abstract

Background

Asthma and chronic obstructive pulmonary disease (COPD) are common chronic respiratory diseases, and some patients have overlapping disease features, termed asthma-COPD overlap (ACO). Patients characterized with ACO have increased disease severity; however, the mechanisms driving this have not been widely studied.

Objectives

This study sought to characterize the phenotypic and transcriptomic features of experimental ACO in mice induced by chronic house dust mite antigen and cigarette smoke exposure.

Methods

Female BALB/c mice were chronically exposed to house dust mite antigen for 11 weeks to induce experimental asthma, cigarette smoke for 8 weeks to induce experimental COPD, or both concurrently to induce experimental ACO. Lung inflammation, structural changes, and lung function were assessed. RNA-sequencing was performed on separated airway and parenchyma lung tissues to assess transcriptional changes. Validation of a novel upstream driver SPI1 in experimental ACO was assessed using the pharmacological SPI1 inhibitor, DB2313.

Results

Experimental ACO recapitulated features of both asthma and COPD, with mixed pulmonary eosinophilic/neutrophilic inflammation, small airway collagen deposition, and increased airway hyperresponsiveness. Transcriptomic analysis identified common and distinct dysregulated gene clusters in airway and parenchyma samples in experimental asthma, COPD, and ACO. Upstream driver analysis revealed increased expression of the transcription factor Spi1. Pharmacological inhibition of SPI1 using DB2313, reduced airway remodeling and airway hyperresponsiveness in experimental ACO.

Conclusions

A new experimental model of ACO featuring chronic dual exposures to house dust mite and cigarette smoke mimics key disease features observed in patients with ACO and revealed novel disease mechanisms, including upregulation of SPI1, that are amenable to therapy.

Le texte complet de cet article est disponible en PDF.

Key words : Asthma COPD overlap, SPI1, transcriptomics, house dust mite, cigarette smoke

Abbreviations used : ACO, AHR, AIR, BALF, ChEA3, COPD, CS, DEG, DEX, FLAME, GO, HDM, log2FC, Padj, RNA-seq, WGCNA


Plan


 Supported by an Australian Government Research Training Program Scholarship to X.T., a Lung Foundation Australia Boehringer Ingelheim Fellowship to R.Y.K., a National Health and Medical Research Council Investigator Grant (1179187) and UTS to P.M.H., and National Health and Medical Research Council Early Career Fellowship (1120152) and grant (1138402) to C.D.
 Disclosure of potential conflict of interest: A. Bosco founded INSiGENe Pty Ltd, co-founded Respiradigm Pty Ltd, and receives consulting fees from Merck Sharp & Dohme outside the submitted work. The rest of the authors declare that they have no relevant conflicts of interest.


© 2022  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 150 - N° 4

P. 817 - octobre 2022 Retour au numéro
Article précédent Article précédent
  • Nasopharyngeal airway dual-transcriptome of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study
  • Zhaozhong Zhu, Carlos A. Camargo, Yoshihiko Raita, Robert J. Freishtat, Michimasa Fujiogi, Andrea Hahn, Jonathan M. Mansbach, Jonathan M. Spergel, Marcos Pérez-Losada, Kohei Hasegawa
| Article suivant Article suivant
  • Feno differentiates epithelial gene expression clusters: Exploratory analysis from the MESOS randomized controlled trial
  • Sarah Diver, Sriram Sridhar, Latifa C. Khalfaoui, Richard J. Russell, Claire Emson, Janet M. Griffiths, Melissa de los Reyes, Da Yin, Gene Colice, Christopher E. Brightling

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.